Authors: Kampf, C.; Carlsson, P- O.

Source: Immunology Endocrine & Metabolic Agents - Medicinal Chemistry (Formerly Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents), Volume 6, Number 2, April 2006 , pp. 167-178(12)

Publisher: Bentham Science Publishers

Abstract:

Pancreatic islet transplantation is a tempting strategy to treat patients with type 1 diabetes mellitus, since if successful it could provide a cure for the disease. At present, there is, however, a poor long-term outcome of such transplantations compared to the results for whole pancreas transplantation. One explanation for this may be inadequate engraftment of the transplanted cells in the new microenvironment. The engraftment process includes immediate survival in the post transplantation phase. There is likely extensive cell death immediately following transplantation mainly due to inflammatory responses triggered by e.g. hypoxia. Also the long-term survival and function of the transplanted islets is encompassed by the term engraftment. This is influenced by the cellular turn-over rate, and the degree of revascularization and reinnervation of the islet tissue. To regain optimal function in surviving cells, new vascular and nervous systems similar to those in endogenous islets need to form. Both qualitative and quantitative changes compared to endogenous islets have, however, been described in the new vascular system that develops following transplantation, and these changes seem to have consequences for islet blood perfusion, metabolism and function. Comparatively little is known regarding the extent of functional re-growth of nerves that occurs, and its influence on graft function. This review also discusses the challenges of engraftment that seem specific for intraportally transplanted islets, e.g. the instant blood mediated immune reaction, the loss of glucagon response to hypoglycemia, and the lower β-cell proliferation rate in intraportally transplanted islets than in islets grafted to the kidney.

Keywords: Islet transplantation; engraftment; liver; hypoxia; revascularization; reinnervation; metabolism; type 1 diabetes

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187152206776359902

Affiliations: 1: Dept. of Medical Cell Biology, Uppsala University, Husargatan 3, Box 571, SE-751 23 Uppsala, Sweden.

Publication date: 2006-04-01

More about this publication?

• Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in the medicinal chemistry and rational drug design for the discovery of new Immunology, Endocrine & Metabolic Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Immunology, Endocrine & Metabolic medicinal chemistry.
  
  Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Immunology, Endocrine & Metabolic drug discovery.

Related content

• In this: publication
• By this: publisher
• In this Subject: Chemistry ,  Allergy & Immunology ,  Pharmacology
• By this author: Kampf, C. ;  Carlsson, P- O.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers